子類別 會議論文/會議摘要 [1/2] 期刊論文 [18/18] 鄰近社群 伍素瑩 [52/65] 其他 [58/60] 夏克山 [76/98] 岳嶽 [29/32] 張仲明 [7/9] 張俊彥 [18/18] 張竣評 [21/26] 徐祖安 [170/215] 李秀珠 [75/105] 李靜琪 [23/24] 洪明秀 [31/40] 潘秀玲(2009-2013) [16/17] 王文傑 [13/15] 王鴻俊 [7/7] 石全(2014-2017) [35/39] 童俊維 [23/23] 紀雅惠 [21/25] 翁紹華 [22/24] 莊宏 [1/1] 葉修華 [24/25] 葉燈光 [133/152] 蔣維棠 [41/66] 謝興邦 [171/231] 趙宇生(2002-2013) [120/212] 郭靜娟 [49/55] 鄒倫 [28/29] 陳志豪 [31/52] 陳新(2002-2015) [53/67] 陳炯東 [180/212] 顏婉菁 [6/7] 許明珠(1997-2001) [3/10] 陳淑貞(1998-2001) [3/11] 陳華鍵(1997-2001) [9/9] 社群統計 近3年內發表的文件:4(20.00%) 含全文筆數:19(95.00%) 文件下載次數統計 下載大於0次:19(100.00%) 下載大於100次:17(89.47%) 檔案下載總次數:7387(0.14%) 最後更新時間: 2024-12-01 03:13 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 DBPR116, a prodrug of BPRMU191, in ... Discovery of a mu-opioid receptor m... Development of furanopyrimidine-bas... Selective and antagonist-dependent ... Colloidal assemblies composed of po... Overcoming vincristine resistance i... Drug-like property optimization: Di... Identification of novel quinoline i... Discovery of clinical candidate DBP... Discovery of a furanopyrimidine-bas...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-20 / 20. (共1頁) 1  每頁顯示[10|25|50]項目

日期	題名	關聯
2024-10-29	DBPR116, a prodrug of BPRMU191, in combination with naltrexone as a safer opioid analgesic than morphine via peripheral administration	Journal of Medicinal Chemistry. 2024 Oct 29;Article in Press.
2024-07-17	Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia	Cell Chemical Biology. 2024 Jul 17;Article in Press.
2023-02-07	Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer	Journal of Medicinal Chemistry. 2023 Feb 7;66(4):2566-2588.
2022-11	Selective and antagonist-dependent µ-opioid receptor activation by the combination of 2-{[2-(6-chloro-3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]sulfanyl}-5-phenyl-4,6-(1H,5H)-pyrimidinedione and naloxone/naltrexone	Bioorganic Chemistry. 2022 Nov;128:Article number 105905.
2021-07-16	Colloidal assemblies composed of polymeric micellar/emulsified systems integrate cancer therapy combining a tumor-associated antigen vaccine and chemotherapeutic regimens	Nanomaterials. 2021 Jul 16;11(7):Article number 1844.
2021-01	Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors	Chemical Biology and Drug Design. 2021 Jan;97(1):51-66.
2020-08	Design of a potent anticancer lead inspired by natural products from traditional Indian medicine	Journal of Biomolecular Structure and Dynamics. 2020 Aug;38(12):3563-3577.
2020-05	Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors	Bioorganic Chemistry. 2020 May;98:Article number 103689.
2020-01	Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening	Biochimie. 2020 Jan;168:220-230.
2019-12	Lysosomal cysteine protease cathepsin S is involved in cancer cell motility by regulating store-operated Ca(2+) entry	Biochimica et Biophysica Acta. Molecular Cell Research. 2019 Dec;1866(12):Article number 118517.
2019-11-27	Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer	Journal of Medicinal Chemistry. 2019 Nov 27;62(22):10108-10123.
2019-10	Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer	Annals of Oncology. 2019 Oct;30(Suppl. 5):789.
2019-04-01	The in vivo antinociceptive and mu-opioid receptor activating effects of the combination of N-phenyl-2′,4′-dimethyl-4,5′-bi-1,3-thiazol-2-amines and naloxone	European Journal of Medicinal Chemistry. 2019 Apr 1;167:312-323.
2018-07	4-Bromophenylhydrazinyl benzenesulfonylphenylureas inhibit indoleamine 2,3-dioxygenase in vitro and in vivo	Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 1664.
2018-04	4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy	Bioorganic Chemistry. 2018 Apr;77:600-607.
2017-01	Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists	European Journal of Medicinal Chemistry. 2017 Jan;126:202-217.
2016-01	Important hydrogen bond networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1	Journal of Medicinal Chemistry. 2016 Jan;59 (1):282-293.
2016-01	Phenyl benzenesulfonylhydrazides exhibit selective Indoleamine 2,3-Dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy	Journal of Medicinal Chemistry. 2016 Jan;59(1):419-430.
2015-10	Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening	Journal of Medicinal Chemistry. 2015 Oct;58 (19):7807-7819.
2014-08	Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors	Bioorganic and Medicinal Chemistry Letters. 2014 Aug;24(15):3403-3406.

顯示項目1-20 / 20. (共1頁) 1  每頁顯示[10|25|50]項目